Stock comparison
Apellis Pharmaceuticals
Genmab A/S
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
APLS
Apellis Pharmaceuticals
Market cap
$5.25B
Sector
Healthcare
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
Overall winner
Apellis Pharmaceuticals APLS
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | APLS | GMAB | Winner |
|---|---|---|---|
| Warren Buffett | 58C | 65C | GMAB |
| Benjamin Graham | 79D | 64C | APLS |
| Philip Fisher | 71C | 48D | APLS |
| Peter Lynch | 81C | 25F | APLS |
| Joel Greenblatt | 63C | 76B | GMAB |
| Charlie Munger | 67D | 68C | GMAB |
| Terry Smith | 65B | 71C | GMAB |
Side-by-side metrics
| Metric | APLS | GMAB |
|---|---|---|
| Market cap | $5.25B | $16.5B |
| P/E (TTM) | 38.8x | 6.2x |
| EV/EBIT | 96.0x | 12.0x |
| ROIC (TTM) | 18.11% | 43.78% |
| Gross margin | 90.12% | 93.88% |
| Net margin | 12.06% | 18.23% |
| Revenue CAGR 5y | 97.06% | -18.45% |
| EPS CAGR 5y | - | -23.48% |
| Debt / Equity | 1.1x | 0.1x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
APLS leads on
- Revenue CAGR 5y97.06%vs -18.45%+119%
GMAB leads on
- Debt / Equity0.1xvs 1.1x+94%
- EV/EBIT12.0xvs 96.0x+88%
- P/E (TTM)6.2xvs 38.8x+84%
- Market cap$16.5Bvs $5.25B+68%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.